Visit Blog
Explore Tumblr blogs with no restrictions, modern design and the best experience.
Fun Fact
Tumblr paired up with Humans of New York to raise money for Hurricane Sandy relief.
#leukemia
Photo
Tumblr media
req’d by @catgirlkirigiri
i have. many. many questions about this one.
because I’m reading it as ‘panicked and wildly inappropriate response to name inquiries when one is a bumbling alien in disguise as an FBI agent’ 
but it could be so much worse
215 notes · View notes
premimtimes · 15 hours ago
Text
We Have Lost Our Innocent, By Chido Onumah
We Have Lost Our Innocent, By Chido Onumah
A man close to his roots, Innocent never stopped talking about retiring to his village in Mbaise in Imo State and starting a local musical group. I still remember teasing him about it during his farewell party at Ford Foundation a few months ago. Whether he meant it or not, we will never know. What we know, sadly, is that we have lost our Innocent, and it hurts!   Two weeks ago, I lost a comrade,…
Tumblr media
View On WordPress
0 notes
Link
Results:  It was observed that propolis has high antioxidant activity, although it has a lower amount of proteins. Propolis has high toxicity and higher antitumoral activity against colon cancer than leukemia.
0 notes
peeterdbmr · a day ago
Link
Hairy cell leukemia is also known as leukemic reticuloendotheliosis is rare blood cancer characterized by unusual changes in B lymphocytes and produce excess white cells in the bone marrow.
0 notes
bulletinwave · a day ago
Text
"Get out of here cancer!": Warrior princess fighting leukemia turns 5
“Get out of here cancer!”: Warrior princess fighting leukemia turns 5
BALTIMORA – Ailani Myers turns 5 on Saturday 17 April. He told WMAR-2 News, “a whole five-year-old girl, girl!” It is a special day for her and her family. “We are so lucky to see her turn five with so much energy and look so beautiful because this summer was very tough. She’s been in the hospital for a while. said Princecine Johnson, Ailani’s mother. Ailani was diagnosed with acute lymphoblastic…
View On WordPress
0 notes
punchyrowrow · 3 days ago
Text
Hi everyone! One of my best friend’s niece was just diagnosed with leukemia. If you can, I would be very great full of you could donate to her go fund me. It would mean the world to all of us!
6 notes · View notes
notreallyimportant · 4 days ago
Text
Tumblr media
How are you going to be prolife, but don’t want to help keep people alive? The bill was still passed, but still.
1 note · View note
clinicalsurgery · 4 days ago
Text
Low Dose Single Agent Chemotherapy Cured a Child with Down syndrome and Acute Myeloid Leukemia in Open Access Journal of Medical and Clinical Surgery by Ghada Basil Kadhim Al odda*
Tumblr media
Abstract
Patient with Down syndrome (trisomy 21) have more than 10-time increasing risk Of Acute Leukemia with more than 1% of children with down syndrome will develop Acute Myeloid Leukemia (AML), this increase risk occurs primarily in children with Down syndrome (DS) under the age of 10 years. Among patients with DS, AML most commonly occur between 1-4 years old age, megakaryocytic AML (M7) which is uncommon subtype of AML mostly affecting patients with DS. We reported a patient with Down syndrome who developed AML M2 (Myeloblastic without maturation) at the age of 2 years who was treated by single agent low dose Cytarabine (Ara-C) chemotherapy because of associated cardiac comorbidity for 24 months, currently she is 4 years off chemotherapy and on complete remission.
Keywords: Down syndrome; Trisomy 21; Acute Myeloid Leukemia; Low dose chemotherapy; Single agent; Atrioventricular septal defect (AVSD).
Abbreviations: AML: Acute Myeloid Leukemia; DS: Down Syndrome; AVS: Aterioventricular septal Defect; EF: Ejection Fraction; CD: Cluster of Differentiation; mg: Milligram; CR: Complete Remission; MRD: Minimal Residual Disease
Introduction
Down syndrome or constitutional trisomy 21 was linked to leukemia for the first time in a case report published in 1930 [1]. Since then, Down syndrome has been recognized as one of the most important leukemia-predisposing syndromes and patients with Down syndrome and leukemia have unique clinical features and significant differences in treatment response and toxicity profiles compared to patients without down syndrome [2]. We reported a patient with Down syndrome and AVSD developed AML M1which was successfully treated. by low dose single agent chemotherapy to prevent potential anthracycline induced cardiotoxicity.
Case Report
A 24 months old female was referred to us by a pediatrician neurosurgeon for further assessment and treatment. The patient was a known case of Down syndrome with large atrioventricular septal defect (AVSD) or what is called endocardial cushion defect with right to left shunt that causing heart failure. She was presented suddenly with Intermittent fever for 3 weeks which was not responding to antipyretic and several courses of antibiotic, progressive pallor, cutaneous bleeding. She was on anti-failure drug (Enalapril tablet 2.5 mg and forusamide 5 mg per day); she was vaccinated according to her age. There is no consanguinity of parents, neither family history of malignancy nor similar condition. In addition to the characteristic physical stigmata of Down syndrome (delayed physical growth, microcephaly, low seated ears, poor muscle tone, grade 4 pan-systolic murmur and other feature of DS), examination revealed fever, pallor, skin ecchymosis, generalized lymphadenopathy and hepatosplenomegaly. Laboratory investigations include liver function tests, renal function tests, serum electrolytes (potassium, sodium, calcium, phosphorus); serum uric acid and coagulation profile (PT and PTT), all were normal. Cerebrospinal fluid cytology (CSF) Cytology was negative for malignant cell. Chest x ray showed cardiomegaly (Figure 1) with Echocardiography revealed Right ventricular hypertrophy and ejection fraction (EF) of 40%.
According to the bone marrow morphology, immunohistochemistry stains and immunophenotype by flow cytometry the diagnosis was AML M1. Cytogenetic analysis by karyotype of the blast cell showed trisomy 21 (DS) without any other chromosomal abnormality and she was categorized as a favorable risk group. The patient was started on supportive care to prevent tumor lysis syndrome (Allopurinol, Hydration). Because of her cardiac problem (heart failure with low baseline EF) and because of the potential cardiotoxicity by anthracycline chemotheray, we discussed her condition with her family and we decided to started her on low dose single agent Cytarabine 10 mg/kg/ dose twice daily by subcutaneous injection for 10 days per 28 days cycle as an outpatient palliative treatment. After two uneventful courses the patient entered complete remission (CR) with negative minimal residual disease (MRD).
We continued chemotherapy for 24 cycles (24 months) without any significant chemotherapy complication but Figure 4: Analysis by flow cytometry showed the blasts positive for, MPO, HLADR, CD7, CD13, CD33, CD34 and CD117 but negative for CD3, CD10, CD14 and CD15. unfortunately her cardiac problem progress, we stopped her chemotherapy and she underwent surgical correction for her atrioventricular septal defect. Now she is 4 years of chemotherapy and she is hematologically in complete remission (CR) and doing well regarding her corrected atrioventricular septal defect.
Discussion
Children with trisomy 21/DS represent a clinically and genetically unique subset of pediatric patients with AML, with patients <4 years of age having a 500-fold increased risk of developing the disease [3]. Approximately 15% of pediatric AML cases occur in DS children. Acute megakaryocytic leukemia (AMkL; M7) is the most common French-American-British subtype of DS AML patients, Other AML French-American-British subtypes have also been described in DS AML including M0, M1/M2, and M6 [4-6]. It is now recognized that DS children with AML have exceptionally high cure rates, which typically have been >80% [7,8]. In view of the high incidence of congenital cardiac defects in DS children, potential concerns exist, particularly with the use of anthracyclines. A recent report from the Children's Oncology Group (COG) Study POG 9421 found an increased frequency of cardiac-related late effects, which used a total cumulative anthracycline (daunorubicin and mitoxantrone) dose of 375 mg/m2, with 24% of DS patients developing cardiomyopathies. In our case report, we presented 2 years old female DS patient who was a known case of heart failure due to an atrioventricular septal defect developed AML M1 which initially manifested as intermittent fever, pallor, bleeding tendency, generalized lymphadenopathy with hepatosplenomegaly. Complete blood picture revealed anemia, thrombocytopenia and leukocytosis. BMA showed 95% blast which was confirmed by immunohistochemistry and flow cytometry as AML M1. Echocardiography was with low EF (40%).
Our patient underwent chemotherapy with low dose cytarabine as she was unfit for aggressive chemotherapy which was used to treated a patient with AML, she responds well to this low dosage therapy and underwent CR, we stopped the chemotherapy after 24 months because her cardiac problem which needed surgical correction. At the time this manuscript was prepared the patient was undergoing regular follow up for the last uneventful 4 years.
Conclusion
Acute Myeloid Leukemia should be considered in the differential diagnosis of DS patient’s experiences cytopenia or leukocytosis. When acute leukemia is suspected clinically, a bone marrow aspirate for morphology, immunohistochemistry staining, immunophenotypes by flow cytometry and cytogenetic should be performed. Echocardiography is always important before starting anthracycline chemotherapy.
Chemotherapy is the treatment of choice for acute myeloid leukemia and usually including combination of two or more chemotherapeutic agent which including anthracycline. Notably, treating DS with AML with single agent cytarabine for a given time interval; depending on the response; May benefit patients who has a significant cardiac dysfunction but a large study are needed to established it is efficacy in patient with DS and AML.
Regarding our Journal: https://oajclinicalsurgery.com/ Know more about this article https://oajclinicalsurgery.com/oajcs.ms.id.10007/ https://oajclinicalsurgery.com/pdf/OAJCS.MS.ID.10007.pdf
0 notes
tusharmahajansblog · 5 days ago
Text
Leukemia Therapeutics Market Size, Trends, Growth and Insights Till 2027
Leukemia Therapeutics Market Research Report: by Type (Chemotherapy, Biological, Targeted, Radiation), by Application (Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia) - Global Forecast Till 2027
Leukemia Therapeutics Market Highlights
The Global Leukemia Therapeutics Market anticipated to have held a market value of USD 10.7 billion in the year 2017 and is expected to grow at a CAGR of 5.3% during the forecast period. Leukemia is blood cancer which most commonly in adults and children. Acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia are the major types of the leukemia. leukemia therapeutics such as chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant are used in treating the leukemia.
Availability of innovative therapies for leukemia, increasing number of cases of leukemia, strong developing pipeline and targeted drug delivery, and increasing older population are expected to drive the growth of market. According to the Leukemia & Lymphoma Society of Canada, in 2016 estimated 22,510 were suffer with leukemia in Canada and 5,900 new cases of leukemia founded in same year. On other hand, high cost required for the development of new therapeutics can restrain the market growth over the assessment period.
Request Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/7425
Regional Analysis
Geographically, the Americas is expected to dominate the global leukemia therapeutics market owing to the presence of well-established players, Availability of innovative therapies for leukemia, increasing number of cases of leukemia, strong developing pipeline and targeted drug delivery, and increasing older population. Europe is expected to hold the second largest position in the global leukemia therapeutics market due to increasing number of cases of leukemia. Asia-Pacific is expected to be the fastest growing leukemia therapeutics market owing to the availability of innovative therapies for leukemia and increasing number of cases of leukemia. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global leukemia therapeutics market.
Segmentation
The global leukemia therapeutics market has been segmented into type, applications, and region.
Based on type, leukemia therapeutics market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.
Based on applications, leukemia therapeutics market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others. The acute lymphocytic leukemia segment is expected to account for the largest share segment of the market in 2017.
Key Players
Some of the prominent players in the global leukemia therapeutics market are Eisai Co., Ltd (Japan), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche AG (Switzerland), Sanofi S.A. (France), Teva Pharmaceutical Industries Ltd (Israel), Amgen Inc (US), and Takeda Pharmaceutical Company Ltd (Japan).
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/leukemia-therapeutics-market-7425
About Market Research Future:        
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: sales@marketresearchfuture.com
0 notes
wikibiofacts · 6 days ago
Text
Who is Azaylia Cain? Wiki, Bio, Age, Hospitalized, Parents, Health
Who is Azaylia Cain? Wiki, Bio, Age, Hospitalized, Parents, Health
Azaylia Cain Wiki -Azaylia Cain Bio Azaylia Cain is the daughter of Ashley Cain and his girlfriend Safiyya Vorajee. They rushed their daughter Azaylia Cain back to the hospital overnight as she courageously battles leukemia. Ashley posted a video of Azaylia in the ambulance to Instagram to update followers. He captioned the posts: “Come on baby” and “I love you, princess.” Age She is 8 months…
Tumblr media
View On WordPress
0 notes
sreerudra · 7 days ago
Text
Heal and Detox After Cancer Without Any Adverse Effect
Cancer is the abnormal cell growth in our body. It happens when gene changes trigger the cells to multiply at a faster rate. If not identified and treated earlier, it can spread to other parts of the body. Cancers are of uncountable types but the most common ones are lymphoma, breast cancer, Leukemia, Pancreatic cancer etc. (Know more)
Tumblr media
0 notes
vensohowlie · 8 days ago
Text
Tumblr media
Tumblr media
The difference cancer makes. Before my leukemia diagnosis and after my chemotherapy.
0 notes
missrobinswritings · 8 days ago
Text
what can happen in two years
if you had walked up to me two years ago and told me what life would be like for me today, I'd laugh in your face. two years ago today I was awaiting to see my boyfriend in person, as he lived 300 miles away at the time. if you would have told me that I now work with him, we live together in my parent's house and are moving into our first apartment together with one of my best friends, I think I would have called you nuts.
if you would have told me my mother's leukemia was actually life threatening, that it would get so much worse, I don't think I would have believed you. "No, it's true," you'd say. "She had to start using her walker again. She started using a wheelchair and was put onto oxygen. She had to go to treatments and bloodwork two times a week each. Eventually, it no longer worked." I'd just say they told us it wasn't life threatening. what do you even know?
oh, and while all this is happening you've been in a global pandemic for over a year now. you were stuck in your house for six months. everyone wears masks, including you at work. speaking of work, you are now an assistant manager at a different location.
I'd walk away. but, alas, every word you said would have been true.
0 notes
dykecharlie · 10 days ago
Text
I'm trying to enjoy this friday night but I just found out the article I planned on presenting in a couple weeks was already taken by another student so I gotta find another (and I can't find a good one) AND my best friend cancelled our plans to hang out (for the first time in MONTHS) this weekend, like she always does, cos they're a very busy bee doing very important work and I'm so proud of them but I miss them!! 💔
0 notes
medicomunicare · 12 days ago
Text
Physical and calorie control against leukemia's marrow residual: the IDEAL trial summary
Physical and calorie control against leukemia’s marrow residual: the IDEAL trial summary
Overweight children and adolescents receiving chemotherapy for treatment of leukemia are less successful battling the disease compared to their lean peers. Now, research conducted at the Cancer and Blood Disease Institute at Children’s Hospital Los Angeles indicates that modest changes in diet and exercise can greatly increase survival in youth treated for acute lymphoblastic leukemia (ALL), the…
View On WordPress
0 notes
jankalyan · 12 days ago
Text
These skin problems can indicate a serious underlying health issues
These skin problems can indicate a serious underlying health issues
New Delhi: Your skin, the largest organ of the human body, reflects everything that is going on inside your system while also acting as a protective barrier from harmful micro-organisms in our environment. Our skin tells us everything we need to know about our physical and mental health, but not everyone knows how to read these signs that could be pointing to more serious underlying health…
View On WordPress
0 notes